Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical ...

Ancora Heart, Inc., a medical device company developing a transcatheter device-based therapy to address heart failure (HF), ...

The treatment for end-stage heart failure continues to rapidly evolve. In the area of mechanical circulatory support, next-generation artificial hearts are ...

SAN FRANCISCO -- Long-term outcomes after transcatheter aortic valve replacement (TAVR) were looking more and more like those ...

Jupiter Endovascular announces positive results from SPIRARE I first-in-human study presented at TCT 2025: Menlo Park, California Tuesday, October 28, 2025, 16:00 Hrs [IST] Jupite ...

Anteris Technologies ( ($AU:AVR) ) has issued an announcement. Anteris Technologies announced favorable one-year clinical outcomes for its DurAVR® ...

Researchers have found in a new study that acute kidney injury is a common and serious complication in patients admitted to ...

Antidepressants induce cardiometabolic and other physiological alterations, which vary between medications, according to a ...

The complications highlight pregnancy as a crucial life opportunity for CV health optimization, said investigators led by ...

Cardiac performance in patients with HF can be determined with measurement of the time for peak oxygen uptake to decrease by more than 12.5%.

GE HealthCare secures CE mark for Carevance, advancing scalable, cost-effective monitoring across care settings.

Results were presented at the Transcatheter Cardiovascular Therapeutics (TCT) Conference 2025 in San Francisco on October 27, 2025DynamX® ...